Human papillomavirus infection in esophageal squamous cell carcinoma and esophageal adenocarcinoma: a concise review.
Barrett's esophagus
DNA
esophageal cancer
human papillomavirus
papilloma
Journal
Annals of the New York Academy of Sciences
ISSN: 1749-6632
Titre abrégé: Ann N Y Acad Sci
Pays: United States
ID NLM: 7506858
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
23
04
2020
revised:
05
09
2020
accepted:
17
09
2020
pubmed:
27
10
2020
medline:
2
2
2021
entrez:
26
10
2020
Statut:
ppublish
Résumé
The causal link between high-risk human papillomavirus (hr-HPV) infection and cervical, anogenital, and some oropharyngeal malignancies has been established by both molecular and epidemiological data. The association between HPV and esophageal squamous cell carcinoma (ESCC) remains controversial, as is the true prevalence of HPV infection in ESCC. The wide range in reported rates reflects variability in the primary literature, with some larger scale case-control studies suggesting the infection rates range from 0% to 78%. Interactions between HPV and the Barrett's metaplasia-dysplasia-carcinoma sequence have been explored, and these studies have shown some conflicting data. Overall, systematic reviews have reported the prevalence of HPV-positive DNA in esophageal adenocarcinoma patients of between 13% and 35%. Postulated reasons for discrepancies in HPV prevalence rates in esophageal cancer include variations in testing methodology and assay sensitivities; technical issues, including the lack of a gold-standard primer; types of specimens utilized (fresh-frozen versus formalin-fixed tissue); geographical variation; cross-contamination; and small sample sizes. Thus, efforts must be undertaken to (1) standardize HPV testing, ideally in a central laboratory and utilizing tests that detect viral transcriptional activity; (2) avoid cross-contamination; and (3) recruit large numbers of patients to accurately ascertain HPV rates in esophageal malignancy.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
36-48Informations de copyright
© 2020 New York Academy of Sciences.
Références
Syrjanen, K., S. Pyrhonen, S. Aukee, et al. 1982. Squamous cell papilloma of the esophagus: a tumour probably caused by human papilloma virus (HPV). Diagn. Histopathol. 5: 291-296.
Syrjanen, K.J. 2002. HPV infections and oesophageal cancer. J. Clin. Pathol. 55: 721-728.
Rajendra, S., B. Wang, E.T. Snow, et al. 2013. Transcriptionally active human papillomavirus is strongly associated with Barrett's dysplasia and esophageal adenocarcinoma. Am. J. Gastroenterol. 108: 1082-1093.
Ludmir, E.B., S.J. Stephens, M. Palta, et al. 2015. Human papillomavirus tumor infection in esophageal squamous cell carcinoma. J. Gastrointest. Oncol. 6: 287-295.
Kunzmann, A.T., S. Graham, C.M. McShane, et al. 2017. The prevalence of viral agents in esophageal adenocarcinoma and Barrett's esophagus: a systematic review. Eur. J. Gastroenterol. Hepatol. 29: 817-825.
Hošnjak, L. & M. Poljak. 2018. A systematic literature review of studies reporting human papillomavirus (HPV) prevalence in esophageal carcinoma over 36 years (1982-2017). Acta Dermatovenerol. Alp. Pannonica Adriat. 27: 127-136.
Pohl, H. & H.G. Welch. 2005. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J. Natl. Cancer Inst. 97: 142-146.
Rajendra, S. & I.K. Robertson. 2010. Similar immunogenetics of Barrett's oesophagus and cervical neoplasia: is HPV the common denominator? J. Clin. Pathol. 63: 1-3.
Wang, B., S. Rajendra, D. Pavey, et al. 2013. Viral load and integration status of high-risk human papillomaviruses in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am. J. Gastroenterol. 108: 1814-1816.
Spechler, S.J. & R.F. Souza. 2014. Barrett's esophagus. N. Engl. J. Med. 371: 836-845.
Antonsson, A., L. Knight, D.C. Whiteman, et al. 2016. Human papillomavirus not detected in esophageal adenocarcinoma tumor specimens. Cancer Epidemiol. 41: 96-98.
El-Serag, H.B., J.M. Hollier, P. Gravitt, et al. 2013. Human papillomavirus and the risk of Barrett's esophagus. Dis. Esophagus 26: 517-521.
Rai, N., G.J. Jenkins, E. McAdam, et al. 2008. Human papillomavirus infection in Barrett's oesophagus in the UK: an infrequent event. J. Clin. Virol. 43: 250-252.
Iyer, A., V. Rajendran, C. Adamson, et al. 2011. Human papillomavirus is detectable in Barrett's esophagus and esophageal carcinoma but is unlikely to be of any etiologic significance. J. Clin. Virol. 50: 205-208.
Li, X., C. Gao, Y. Yang, et al. 2014. Systematic review with meta-analysis: the association between human papillomavirus infection and oesophageal cancer. Aliment. Pharmacol. Ther. 39: 270-281.
Abeid, M., S. Labib & E. Neizamy. 2011. Esophageal squamous papilloma. Gastrointest. Endosc. 73: 1035.
Takeshita, K., S.-I. Murata, S. Mitsufuji, et al. 2006. Clinicopathological characteristics of esophageal squamous papillomas in Japanese patients-with comparison of findings from Western countries. Acta Histochem. Cytochem. 39: 23-30.
Al Juboori, A.M., Z. Afzal, N. Ahmed, et al. 2015. Esophageal squamous cell papilloma: a not-so-rare cause of dysphagia. Gastroenterol. Hepatol. (N.Y.) 11: 815-816.
Lavergne, D. & E.M. de Villiers. 1999. Papillomavirus in esophageal papillomas and carcinomas. Int. J. Cancer 80: 681-684.
Petrick, J., A. Wyss, A. Butler, et al. 2014. Prevalence of human papillomavirus among oesophageal squamous cell carcinoma cases: systematic review and meta-analysis. Br. J. Cancer 110: 2369-2377.
Tiftikçi, A., E. Kutsal, E. Altıok, et al. 2017. Analyzing esophageal squamous cell papillomas for the presence of human papilloma virus. Turk. J. Gastroenterol. 28: 176-178.
Pantham, G., S. Ganesan, D. Einstadter, et al. 2017. Assessment of the incidence of squamous cell papilloma of the esophagus and the presence of high-risk human papilloma virus. Dis. Esophagus 30: 1-5.
Bray, F., J. Ferlay, I. Soerjomataram, et al. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68: 394-424.
Arnold, M., I. Soerjomataram, J. Ferlay, et al. 2015. Global incidence of oesophageal cancer by histological subtype in 2012. Gut 64: 381-387.
Chen, W., R. Zheng, P.D. Baade, et al. 2016. Cancer statistics in China, 2015. CA Cancer J. Clin. 66: 115-132.
Thun, M.J., M.S. Linet, J.R. Cerhan, et al. 2018. Schottenfeld and Fraumeni Cancer Epidemiology and Prevention. New York, NY: Oxford University Press.
Abnet, C.C., M. Arnold & W.Q. Wei. 2018. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology 154: 360-373.
Liyanage, S.S., B. Rahman, I. Ridda, et al. 2013. The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysis. PLoS One 8: e69238.
Syrjänen, K. 2013. Geographic origin is a significant determinant of human papillomavirus prevalence in oesophageal squamous cell carcinoma: systematic review and meta-analysis. Scand. J. Infect. Dis. 45: 1-18.
Hardefeldt, H., M. Cox, G.J.E. Eslick, et al. 2014. Association between human papillomavirus (HPV) and oesophageal squamous cell carcinoma: a meta-analysis. Epidemiol. Infect. 142: 1119-1137.
Matsha, T., R. Erasmus, A.B. Kafuko, et al. 2002. Human papillomavirus associated with oesophageal cancer. J. Clin. Pathol. 55: 587-590.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. 2012. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr. Eval. Carcinog. Risks Hum. 100: 1-441.
Kumar, B., K.G. Cordell, J.S. Lee, et al. 2008. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J. Clin. Oncol. 26: 3128.
Ishikawa, M., T. Fujii, M. Saito, et al. 2006. Overexpression of p16INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia. Int. J. Gynecol. Cancer 16: 347.
Lakshmi, S., P. Rema & T.J.P. Somanathan. 2009. P16ink4a is a surrogate marker for high-risk and malignant cervical lesions in the presence of human papillomavirus. Pathobiology 76: 141-148.
Ang, K.K., J. Harris, R. Wheeler, et al. 2010. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363: 24-35.
Shi, W., H. Kato, B. Perez-Ordonez, et al. 2009. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J. Clin. Oncol. 27: 6213-6221.
Mulvany, N.J., D.G. Allen & S.M.J.P. Wilson. 2008. Diagnostic utility of p16:INK4a a reappraisal of its use in cervical biopsies. Pathology 40: 335-344.
Chung, C.H. & D. Raben. 2010. p16 expression as a predictive biomarker of hypoxic cell-sensitizing agents in oropharyngeal cancer. J. Clin. Oncol. 28: 4103-4104.
Marur, S., G. D'Souza, W.H. Westra, et al. 2010. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 11: 781-789.
Michaelsen, S.H., C.G. Larsen & C. von Buchwald. 2014. Human papillomavirus shows highly variable prevalence in esophageal squamous cell carcinoma and no significant correlation to p16INK4a overexpression: a systematic review. J. Thorac. Oncol. 9: 865-871.
Lofdahl, H.E., J. Du, A. Nasman, et al. 2012. Prevalence of human papillomavirus (HPV) in oesophageal squamous cell carcinoma in relation to anatomical site of the tumour. PLoS One 7. e46538.
Zhou, C., J. Li & Q. Li. 2017. CDKN2A methylation in esophageal cancer: a meta-analysis. Oncotarget 8: 50071-50083.
Sitas, F., M. Urban, L. Stein, et al. 2007. The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infect. Agents Cancer 2: 6.
Naucler, P., H.-C. Chen, K. Persson, et al. 2007. Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study. J. Gen. Virol. 88: 814-822.
Herrero, R., X. Castellsague, M. Pawlita, et al. 2003. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J. Natl. Cancer Inst. 95: 1772-1783.
D'Souza, G., A.R. Kreimer, R. Viscidi, et al. 2007. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 356: 1944-1956.
Sitas, F., S. Egger, M.I. Urban, et al. 2012. InterSCOPE study: associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. J. Natl. Cancer Inst. 104: 147-158.
Halec, G., M. Schmitt, S. Egger, et al. 2016. Mucosal alpha-papillomaviruses are not associated with esophageal squamous cell carcinomas: lack of mechanistic evidence from South Africa, China and Iran and from a world-wide meta-analysis. Int. J. Cancer 139: 85-98.
Rajendra, S., B. Wang, D. Pavey, et al. 2015. Persistence of human papillomavirus, overexpression of p53, and outcomes of patients after endoscopic ablation of Barrett's esophagus. Clin. Gastroenterol. Hepatol. 13: 1364-1368.e5.
Ojesina, A.I., L. Lichtenstein, S.S. Freeman, et al. 2014. Landscape of genomic alterations in cervical carcinomas. Nature 506: 371-375.
Agrawal, N., M.J. Frederick, C.R. Pickering, et al. 2011. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333: 1154-1157.
Braakhuis, B.J., P.J. Snijders, W.-J.H. Keune, et al. 2004. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J. Natl. Cancer Inst. 96: 998-1006.
Wong, M.Y.W., B. Wang, A. Yang, et al. 2018. Human papillomavirus exposure and sexual behavior are significant risk factors for Barrett's dysplasia/esophageal adenocarcinoma. Dis. Esophagus 31. https://doi.org/10.1093/dote/doy051
Rajendra, S. & P. Sharma. 2019. Transforming human papillomavirus infection and the esophageal transformation zone: prime time for total excision/ablative therapy? Dis. Esophagus 32. https://doi.org/10.1093/dote/doz008
Furihata, M., Y. Ohtsuki, S. Ogoshi, et al. 1993. Prognostic significance of human papillomavirus genomes (type-16,-18) and aberrant expression of p53 protein in human esophageal cancer. Int. J. Cancer 54: 226-230.
Dreilich, M., M. Bergqvist, M. Moberg, et al. 2006. High-risk human papilloma virus (HPV) and survival in patients with esophageal carcinoma: a pilot study. BMC Cancer 6: 94.
Antonsson, A., A.C. Green, K.-A. Mallitt, et al. 2010. Prevalence and stability of antibodies to 37 human papillomavirus types-a population-based longitudinal study. Virology 407: 26-32.
Hippeläinen, M., M. Eskelinen, P. Lipponen, et al. 1993. Mitotic activity index, volume corrected mitotic index and human papilloma-virus suggestive morphology are not prognostic factors in carcinoma of the oesophagus. Anticancer Res. 13: 677-681.
Wang, W.L., Y.C. Wang, C.T. Lee, et al. 2015. The impact of human papillomavirus infection on the survival and treatment response of patients with esophageal cancers. J. Dig. Dis. 16: 256-263.
Cao, F., W. Zhang, F. Zhang, et al. 2014. Prognostic significance of high-risk human papillomavirus and p16INK4A in patients with esophageal squamous cell carcinoma. Int. J. Clin. Exp. Med. 7: 3430.
Kumar, R., S.K. Ghosh, A.K. Verma, et al. 2015. P16 expression as a surrogate marker for HPV infection in esophageal squamous cell carcinoma can predict response to neo-adjuvant chemotherapy. Asian Pac. J. Cancer Prev. 16: 7161-7165.
Rajendra, S., B. Wang, N. Merrett, et al. 2016. Genomic analysis of HPV-positive versus HPV-negative oesophageal adenocarcinoma identifies a differential mutational landscape. J. Med. Genet. 53: 227-231.
Rajendra, S., W. Xuan, N. Merrett, et al. 2018. Survival rates for patients with Barrett high-grade dysplasia and esophageal adenocarcinoma with or without human papillomavirus infection. JAMA Netw. Open 1: e181054.
Ragin, C.C.R. & E. Taioli. 2007. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int. J. Cancer 121: 1813-1820.
O'rorke, M., M. Ellison, L. Murray, et al. 2012. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol. 48: 1191-1201.
Rajendra, S., P. Sharma, S.D. Gautam, et al. 2020. Association of biomarkers for human papillomavirus with survival among adults with Barrett high-grade dysplasia and esophageal adenocarcinoma. JAMA Netw. Open 3: e1921189.
Chang, F., S. Syrjänen, L. Wang, et al. 1992. Infectious agents in the etiology of esophageal cancer. Gastroenterology 103: 1336-1348.
Yong, F., N. Xudong & T. Lijie. 2013. Human papillomavirus types 16 and 18 in esophagus squamous cell carcinoma: a meta-analysis. Ann. Epidemiol. 23: 726-734.
Bhatia, A. & B. Burtness. 2015. Human papillomavirus-associated oropharyngeal cancer: defining risk groups and clinical trials. J. Clin. Oncol. 33: 3243.
Rajendra, S., W. Xuan, K. Hufnagel, et al. 2020. Antibodies against human papillomavirus proteins in Barrett's dysplasia and intramucosal esophageal adenocarcinoma. Ann. N.Y. Acad. Sci. 1470: 44-56.
Lagergren, J., Z. Wang, R. Bergström, et al. 1999. Human papillomavirus infection and esophageal cancer: a nationwide seroepidemiologic case-control study in Sweden. J. Natl. Cancer Inst. 91: 156-162.
Han, C., G. Qiao, N.L. Hubbert, et al. 1996. Serologic association between human papillomavirus type 16 infection and esophageal cancer in Shaanxi Province, China. J. Natl. Cancer Inst. 88: 1467-1471.
Bjørge, T., T. Hakulinen, A. Engeland, et al. 1997. A prospective, seroepidemiological study of the role of human papillomavirus in esophageal cancer in Norway. Cancer Res. 57: 3989-3992.
Dillner, J., P. Knekt, J. Schiller, et al. 1995. Prospective seroepidemiological evidence that human papillomavirus type 16 infection is a risk factor for oesophageal squamous cell carcinoma. BMJ 311: 1346.
Hindson, B.J., K.D. Ness, D.A. Masquelier, et al. 2011. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 83: 8604-8610.
Sedlak, R.H. & K.R. Jerome. 2013. Viral diagnostics in the era of digital polymerase chain reaction. Diagn. Microbiol. Infect. Dis. 75: 1-4.
Parameshwaran, K., P. Sharma, S. Rajendra, et al. 2019. Circulating human papillomavirus DNA detection in Barrett's dysplasia and esophageal adenocarcinoma. Dis. Esophagus 32: doz064.
Schache, A., T. Liloglou, J. Risk, et al. 2013. Validation of a novel diagnostic standard in HPV-positive oropharyngeal squamous cell carcinoma. Br. J. Cancer 108: 1332-1339.
Mirghani, H., O. Casiraghi, F. Amen, et al. 2015. Diagnosis of HPV-driven head and neck cancer with a single test in routine clinical practice. Mod. Pathol. 28: 1518-1527.
Andl, T., T. Kahn, A. Pfuhl, et al. 1998. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res. 58: 5-12.
Weinberger, P.M., Z. Yu, B.G. Haffty, et al. 2006. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J. Clin. Oncol. 24: 736-747.
Rajendra, S., T. Yang, W. Xuan, et al. 2017. Active human papillomavirus involvement in Barrett's dysplasia and oesophageal adenocarcinoma is characterized by wild-type p53 and aberrations of the retinoblastoma protein pathway. Int. J. Cancer 141: 2037-2049.
Rischin, D., R.J. Young, R. Fisher, et al. 2010. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J. Clin. Oncol. 28: 4142.
Mork, J., A.K. Lie, E. Glattre, et al. 2001. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N. J. Engl. Med. 344: 1125-1131.
Smith, E.M., J.M. Ritchie, M. Pawlita, et al. 2007. Human papillomavirus seropositivity and risks of head and neck cancer. Int. J. Cancer 120: 825-832.
Achour, M., D. Zeghal, L. Kochbati, et al. 2008. Antibody response for L1, E6, E7 HPV 16, and HPV 18 antigens in Tunisian women with cervical cancer. J. Immunoassay Immunochem. 30: 82-96.
Meschede, W., K. Zumbach, J. Braspenning, et al. 1998. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J. Clin. Microbiol. 36: 475-480.
Reuschenbach, M., T. Waterboer, K.L. Wallin, et al. 2008. Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers. Int. J. Cancer 123: 2626-2631.
Hosch, S.B., J.R. Izbicki, U. Pichlmeier, et al. 1997. Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int. J. Cancer 74: 582-587.
Best, S.R., K.J. Niparko & S.I. Pai. 2012. Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers. Otolaryngol. Clin. North Am. 45: 807-822.
Kenter, G.G., M.J. Welters, A.R.P. Valentijn, et al. 2009. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361: 1838-1847.
Harper, D.M., P. Nieminen, G. Donders, et al. 2019. The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: randomized controlled phase II trial with 2.5 years of follow-up. Gynecol. Oncol. 153: 521-529.
Trimble, C.L., M.P. Morrow, K.A. Kraynyak, et al. 2015. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet North Am. Ed. 386: 2078-2088.